Comparative study of the anti-edematogenic effects of anethole and estragole

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 984-990

  Ponte, Edson L ^a   Sousa, Paloma L ^a   Rocha, Maria V A P ^a   Soares, Pedro M G ^a,b   Coelho de Souza, Andrelina N ^a   Leal Cardoso, José H ^a   Assreuy, Ana M S ^a  

^a STATE UNIVERSITY OF CEARÁ   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Anethole; Anti inflammatory; Estragole; Mice; Paw edema

Indexed keywords

ANETHOLE; BRADYKININ; CARRAGEENAN; ESSENTIAL OIL; ESTRAGOLE; HISTAMINE; NITROPRUSSIDE SODIUM; SEROTONIN; SUBSTANCE P; TERPENE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTI EDEMATOGENIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ISOMER; MOUSE; NONHUMAN; PAW EDEMA; PLETHYSMOGRAPHY; SINGLE DRUG DOSE; SWISS WEBSTER MOUSE;

EID: 84867667066     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70895-2     Document Type: Article

References (33)

1. Abraham SK: Anti-genotoxicity of trans-anethole and eugenol in mice. Food Chem Toxicol, 2001, 39, 493-498.
2. Adams HR: Physiologic, pathophysiologic and therapeutic implications for endogenous nitric oxide. J Am Med Assoc, 1996, 209, 1297-1302.
3. Albuquerque AAC, Viana GBS, Silva EAT, Matos FJA: Pharmacological effects of active components of Croton zehntneri essential oil in isolated nerves (Portuguese). Cienc Cult, 1981, 33, 722.
4. Astani A, Reichling R, Schnitzler P: Screening for antiviral activities of isolated compounds from essential oils. Evid Based Complement Alternat Med, 2009, 2011, 1-8.
5. Bristol DW: NTP 3-month toxicity studies of estragole (CAS No. 140-67-0) administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser, 2011, 82, 1-111.
6. Chainy GB, Manna SK, Chaturvedi MM, Aggarwal BB: Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-κB, AP-1, JNK, MAPKK and apoptosis. Oncogene, 2000, 19, 2943-2950. (Pubitemid 30389084)
7. Choo EJ, Rhee YH, Jeong SJ, Lee HJ, Kim HS, Ko HS, Kim JH et al.: Anethole exerts antimetastatic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull, 2011, 34, 41-46.
8. Dallmeir K, Carlini EA: Anesthetic, hypothermic, myorelaxant and anticonvulsant effects of synthetic eugenol derivates and natural analogues. Pharmacology, 1981, 22, 113-127.
9. De Las Heras B, Hortelano S: Molecular basis of the anti-inflammatory effects of terpenoids. Inflamm Allergy Drug Targets, 2009, 8, 28-39.
10. De Vincenzi M, Silano M, Maialetti F, Scazzocchio B: Constituents of aromatic plants: II. Estragole. Fitoterapia, 2000, 71, 725-729.
11. Ferreira SH, Moncada S, Parsons, M, Vane JR: The concomitant release of bradykinin and prostaglandin in the inflammatory response to carrageenan. Br J Pharmacol, 1974, 52, 108-109.
12. Freire RS, Morais SM, Catunda-Junior FEA, Pinheiro DCN: Synthesis and antioxidant, anti-inflammatory and gastroprotector activities of anethole and related compounds. Bioorg Med Chem, 2005, 13, 4353-4358. (Pubitemid 40789919)
13. Ianaro A, O'Donnell CA, Di Rosa M, Liew FY: A nitric oxide synthase inhibitor reduces inflammation, downregulates inflammatory cytokines and enhances interleukin-10 production in carrageenan-induced oedema in mice. Immunology, 1994, 82, 370-375. (Pubitemid 24251618)
14. Landucci ECT, Antunes E, Donato JL, Faro R, Hyslop S, Marangoni S, Oliveira B et al.: Inhibition of carrageenan- induced rat paw oedema by crotapotin, a polypeptide complexed with phospholipase A2. Br J Pharmacol, 1995, 114, 578-583.
15. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL: International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev, 2005, 57, 27-77. (Pubitemid 40283969)
16. Loureiro-Silva MR, Molina HM, Borges DR: Vasoactive substances and modulation of hepatic microvascular system. Rev Assoc Med Bras, 1999, 45, 206-216.
17. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev, 1991, 43, 109-142.
18. Mossner R, Lesch KP: Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun, 1998, 12, 249-271. (Pubitemid 29224829)
19. Newberne R, Smith RL, Doull J, Goodman JI, Munro IC, Portoghese PS, Wagner R BM et al.: The FEMA GRAS assessment of trans-anethole used as a flavoring substance. Food Chem Toxicol, 1999, 37, 789-811. (Pubitemid 29397368)
20. Ohta Y, Kobayashi T, Ishiguro I: Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanaesthetised rats with a single treatment of compound 48/80, a mast cell degranulator. Pharmacol Res, 1999, 39, 261-267. (Pubitemid 29182324)
21. Oliveira AC, Leal-Cardoso JH, Santos CF, Morais, SM, Coelho-de-Souza AN: Antinociceptive effects of the essential oil of Croton zehntneri in mice. Bras J Med Biol Res, 2001, 34, 1471-1474. (Pubitemid 34036852)
22. Payan DG: Neuropeptides and inflammation: the role of substance P. Annu Rev Med, 1989, 40, 341-352.
23. Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, Cirino G: Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol, 2004, 142, 331-338. (Pubitemid 38746169)
24. Rocha APC, Kraychete DC, Lemonica L, Carvalho LR, Barros GAM, Garcia JBS, Sakata RK: Pain: Current aspects of peripheral and central sensitization (Portuguese). Rev Bras Anestesiol, 2007, 57, 94-105. (Pubitemid 46168958)
25. Salminen A, Lohtonen M, Souuronen K, Houuskonen J: Terpenoids: natural inhibitors of NF-kB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci, 2008, 65, 2979-2999.
26. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA, 1993, 90, 7240-7244. (Pubitemid 23222425)
27. Shahat AA, Ibrahim AY, Hendawy SF, Omer EA, Mammouda FM, Abdel-Rahman FH, Saleh MA: Chemical composition, antimicrobial and antioxidant activities of essential oils from organically cultivated fennel cultivars. Molecules, 2011, 16, 1366-1377.
28. Siqueira RJB, Magalhǎ;es PJC, Leal-Cardoso JH, Duarte GP, Lahlou S: Cardiovascular effects of the essential oil of Croton zehntneri leaves and its main constituents, anethole and estragole, in normotensive conscious rats. Life Sci, 2006, 78, 2365-2372.
29. Smith RL, Adams TB, Doull J, Feron VJ, Goodman JI, Marnett LJ, Portoghese PS et al.: Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. Food Chem Toxicol, 2002, 40, 851-870. (Pubitemid 34626695)
30. Soares PMG, Lima RF, Pires AF, Souza EP, Assreuy AMS, Criddle DN: Effects of anethole and structural analogues on the contractility of rat isolated aorta: Involvement of voltage-dependent Ca2+-channels. Life Sci, 2007, 81, 1085-1093. (Pubitemid 47418849)
31. Tognolini M, Ballabeni V, Bertoni S, Bruni R, Impicciatore M, Barocelli E: Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. Pharmacol Res, 2007, 56, 254-260. (Pubitemid 47321209)
32. Vinegar R, Schreiber W, Hugo R: Biphasic development of carrageenan oedema in rats. J Pharmacol Exp Ther, 1969, 166, 96-103.
33. Yea SS, Jeong HS, Choi CY, Park KR, Oh S, Shin JG, Yun CH: Inhibitory effect of anethole on T-lymphocyte proliferation and interleukin-2 production through down-regulation of the NF-AT and AP-1. Toxicol In Vitro, 2006, 20, 1098-1105. (Pubitemid 44067373)